statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference Acurx Pharmaceuticals Announces Presentation of Ibezapolstat...

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference Acurx Pharmaceuticals Announces Presentation of...

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the...

Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV

Acurx Pharmaceuticals (NASDAQ:ACXP  Get Free Report) had its price objective reduced by equities researchers at HC Wainwright from $14.00 to $12.00 in a report issued on Tuesday, Benzinga...

Acurx Pharmaceuticals (NASDAQ:ACXP) Price Target Cut to $12.00

Acurx Pharmaceuticals (NASDAQ:ACXP  Get Free Report) had its price target decreased by stock analysts at HC Wainwright from $14.00 to $12.00 in a research report issued on Tuesday, Benzinga...

Acurx Pharmaceuticals (NASDAQ:ACXP) Price Target Cut to $12.00 by Analysts at HC Wainwright

Q4 2023 Acurx Pharmaceuticals Inc Earnings Call Transcript

Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers...

Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides...

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

A Preview Of Acurx Pharmaceuticals's Earnings

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update Acurx Pharmaceuticals, Inc. to Discuss Fourth...

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Volume	25,535.00
52-Wk High	$8.82
52-Wk Low	$1.17

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.15	--	--	N/A
Q4'23	-$0.25	-$0.37	-51.02%	MISSED
Q3'23	-$0.27	-$0.24	11.11%	BEAT
Q2'23	-$0.23	-$0.28	-20.00%	MISSED
Q1'23	-$0.24	-$0.25	-6.38%	MISSED

ACXP Acurx Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals